BioCentury | Mar 19, 2007
Company News

MacroArray, Abbott deal

...MAb assay. MacroArray has completed blinded clinical studies using the urine-based prostate cancer test . MacroArray...
...systems. MacroArray has the right to issue two additional licenses. Financial terms were not disclosed. MacroArray Technologies LLC...
BioCentury | Oct 6, 2003
Company News

Amersham sales and marketing update

...ImageQuant TL imaging software for analyzing biological samples, including 1D gels, simple 2D gels, and macroarray...
BioCentury | Dec 10, 2001
Company News

bioMerieux, ExonHit, Spectral Diagnostics deal

ExonHit and bioMerieux business bioMerieux-Pierre Fabre (Marcy l’Etoile, France) entered a 5-year deal to develop ExonHit’s Proof-Hit cancer diagnostic for breast and colon cancer. ExonHit will apply its differential analysis of transcripts with alternative splicing...
BioCentury | Dec 6, 2001
Company News

ExonHit, bioMerieux cancer diagnostics deal

ExonHit (Paris, France) and bioMerieux - Pierre Fabre (Marcy l'Etoile, France) entered a 5-year deal to develop ExonHit's Proof-Hit cancer diagnostic for breast and colon cancer. ExonHit's differential analysis of transcripts with alternative splicing (DATAS) technology...
Items per page:
1 - 4 of 4
BioCentury | Mar 19, 2007
Company News

MacroArray, Abbott deal

...MAb assay. MacroArray has completed blinded clinical studies using the urine-based prostate cancer test . MacroArray...
...systems. MacroArray has the right to issue two additional licenses. Financial terms were not disclosed. MacroArray Technologies LLC...
BioCentury | Oct 6, 2003
Company News

Amersham sales and marketing update

...ImageQuant TL imaging software for analyzing biological samples, including 1D gels, simple 2D gels, and macroarray...
BioCentury | Dec 10, 2001
Company News

bioMerieux, ExonHit, Spectral Diagnostics deal

ExonHit and bioMerieux business bioMerieux-Pierre Fabre (Marcy l’Etoile, France) entered a 5-year deal to develop ExonHit’s Proof-Hit cancer diagnostic for breast and colon cancer. ExonHit will apply its differential analysis of transcripts with alternative splicing...
BioCentury | Dec 6, 2001
Company News

ExonHit, bioMerieux cancer diagnostics deal

ExonHit (Paris, France) and bioMerieux - Pierre Fabre (Marcy l'Etoile, France) entered a 5-year deal to develop ExonHit's Proof-Hit cancer diagnostic for breast and colon cancer. ExonHit's differential analysis of transcripts with alternative splicing (DATAS) technology...
Items per page:
1 - 4 of 4